DDIT3 and lymphoma: In summary, our data show that KAT/3BP exhibits significant in vitro and in vivo antitumor activity in lymphoma models, including those with primary resistance to R-CHOP and antibody–drug conjugates, as well as secondary resistance to BTK and PI3K inhibitors.